China Blood Product Industry Report, 2012-2015

NEW YORK, July 17, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

China Blood Product Industry Report, 2012-2015

http://www.reportlinker.com/p057164/China-Blood-Product-Industry-Report-2012-2015.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Blood_Supply,_Tissue_Banking_and_Transplantation

Plasma is a key raw material of the blood product industry. In August 2011, China shut down 16 plasma stations in Guizhou, resulting in a decrease of 15% in the plasma volume of the year. However, due to the implementation of favorable policies, widening gap between supply and demand, rising product prices and other factors, more than 150 plasma stations in China produced about 3,600 tons of plasma in 2012, up 14.2% year on year. From 2012 to mid-2013, new plasma stations of some Chinese enterprises have started plasma collection or obtained plasma collection permits, such as Yuechi plasma station of Jiangxi Boya Bio-Pharmaceutical, Changyuan plasma station of Hualan Bio, and Caoxian plasma station of China Biologic Products. It's expected that China's plasma supply tension will be further eased after 2013.

According to the lot release statistics of National Institutes for Food and Drug Control, in the first ten months of 2012, China's total lot release volume of blood products was about 36.13 million bottles, an increase of 7.1% compared with the full year of 2011. In addition, except human coagulation factor VIII with a decreased lot release volume, other products saw growing release volume. In particular, human immunoglobulin, tetanus immunoglobulin, human fibrinogen, imported human serum albumin witnessed higher growth rates of 321%, 95%, 79%, 45% respectively in the first ten months of 2012. However, Chinese blood product enterprises have weak R&D capability, low plasma utilization and fewer product varieties. The domestic market is still dominated by technically undemanding human serum albumin and human immunoglobulin (ph4) for intravenous injection, which accounted for more than 60% of the lot release volume in 2012. In order to ease the domestic shortage of blood products, China has allowed the import of human serum albumin and recombinant coagulation factor VIII in recent years. Human serum albumin imports have grown rapidly due to low prices. The lot release volume was 8.51 million bottles in the first ten months of 2012, occupying 47.5% of the lot release volume of such products (43.3% in 2011); Behring, Baxter, Instituto Grifols and Octapharma were top four companies by lot release volume. However, due to high prices and national policy restrictions, the import of recombinant coagulation factor VIII is very small, only Bayer and Baxter products were allowed to be imported as of the end of 2012.

China Blood Product Industry Report, 2012-2015 covers the followings:

Plasma volume, plasma station distribution, market size and supply & demand of China blood product industry; Competition pattern, policy environment and import & export of China blood product industry; Market supply & demand and competition pattern of eight categories of blood products including human serum albumin, human immunoglobulin (ph4) for intravenous injection, coagulation factors in China; Development, operation, plasma stations and lot release volume of 12 local blood product producers in China. As of the end of 2012, there were about 30 enterprises passing GMP certification and in normal operation, among them, only Hualan Bio, Tiantan Biological Products (including Chengdu Ronsen), Shanghai RAAS, Yuanda Shuyang Pharmaceutical, China Biologic Products have an annual plasma volume of over 300 tons. In 2012, the five enterprises accounted for 56.1% of China's total plasma volume, and about 30% of China's blood product market revenue. Guangdong Shuanglin Bio-pharmacy, the sixth place holder, had nine plasma stations (three under construction) in 2012, with a plasma volume of about 247 tons and blood product revenue of RMB 431 million. The company has held the largest lot release volume of rabies immunoglobulin in recent years. Jiangxi Boya, though occupying a small market share (1.8% in 2012 by sales), has seven plasma stations, with output and sales volume expected to be further enhanced in the future. 1. Profile of Blood Products1.1 Definition1.2 Classification1.3 Recombinant Blood Products1.4 Industry Chain1.5 Features

2. Overview of China Blood Products Industry

2.1 Market Size

2.2 Development Status

2.3 Supply & Demand

2.3.1 Supply

2.3.2 Demand

2.4 Market Competition

2.5 Operating Environment

2.5.1 International Market

2.5.2 Policies

2.5.3 Domestic Biopharmaceutical Market

2.6 Import & Export

3. Blood Product Market Segments in China3.1 Human Albumin3.1.1 Supply & Demand3.1.2 Competition Pattern3.1.3 Prospects3.2 Human Immunoglobulin (pH4) for Intravenous Injection3.2.1 Supply & Demand3.2.2 Competition Pattern3.3 Coagulation Factor VIII3.3.1 Supply & Demand3.3.2 Competition Pattern3.3.3 Prospects3.4 Hepatitis B Immunoglobulin3.4.1 Supply & Demand3.4.2 Competition Pattern3.5 Human Immunoglobulin3.5.1 Supply & Demand3.5.2 Competition Pattern3.6 Human Prothrombin Complex3.6.1 Supply & Demand3.6.2 Competition Pattern3.7 Tetanus Immunoglobulin3.7.1 Supply & Demand3.7.2 Competition Pattern3.8 Rabies Immunoglobulin3.8.1 Supply & Demand3.8.2 Competition Pattern

4. Key Companies in China

4.1 China Biologic Products Inc.

4.1.1 Profile

4.1.2 Operation

4.1.3 Revenue Structure

4.1.4 Clients and Suppliers

4.1.5 R&D and Investment

4.1.6 Shandong Taibang Biological Products Co., Ltd.

4.1.7 Guiyang Qianfeng Biological Products Co., Ltd.

4.1.8 Xi'an Hui Tian Blood Products Co., Ltd.

4.1.9 Development and Prospects

4.2 Hualan Biological Engineering Inc.

4.2.1 Profile

4.2.2 Operation

4.2.3 Revenue Structure

4.2.4 Gross Margin

4.2.5 Clients and Suppliers

4.2.6 R&D and Investment

4.2.7 Blood Products

4.2.8 Development and Prospects

4.3 Shanghai RAAS Blood Products Co., Ltd.

4.3.1 Profile

4.3.2 Operation

4.3.3 Revenue Structure

4.3.4 Gross Margin

4.3.5 Clients and Suppliers

4.3.6 R&D and Investment

4.3.7 Development and Prospects

4.4 Beijing Tiantan Biological Products Co., Ltd.

4.4.1 Profile

4.4.2 Operation

4.4.3 Revenue Structure

4.4.4 Clients and Suppliers

4.4.5 Gross Margin

4.4.6 R&D and Investment

4.4.7 Blood Products (Chengdu Ronsen Pharmaceutical Co., Ltd.)

4.4.8 Development and Prospects

4.5 Zhenxing Biopharmaceutical & Chemical Inc.

4.5.1 Profile

4.5.2 Operation

4.5.3 Revenue Structure

4.5.4 Gross Margin

4.5.5 Clients and Suppliers

4.5.6 R&D and Investment

4.5.7 Blood Products (Guangdong Shuanglin Bio-Pharmacy Co., Ltd.)

4.5.8 Development and Prospects

4.6 Jiangxi Boya Biopharmaceutical Co., Ltd.

4.6.1 Profile

4.6.2 Operation

4.6.3 Revenue Structure

4.6.4 Gross Margin

4.6.5 Clients and Suppliers

4.6.6 R&D and Investment

4.6.7 Development and Prospects

4.7 Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

4.7.1 Profile

4.7.2 Blood Products

4.8 CNBG Shanghai Institute of Biological Products

4.8.1 Profile

4.8.2 Blood Products

4.9 Shanxi Kangbao Biological Product Co., Ltd.

4.9.1 Profile

4.9.2 Blood Products

4.10 Green Cross

4.10.1 Profile

4.10.2 Blood Products

4.11 Humanwell Healthcare (Group) Co., Ltd.

4.11.1 Profile

4.11.2 Operation

4.11.3 Blood Products (Wuhan Zhongyuan Ruide Biological Products Co., Ltd.)

4.12 Walvax Biotechnology Co, Ltd.

4.12.1 Profile

4.12.2 Operation

4.12.3 Blood Products (Hebei Daan Pharmaceutical Co., Ltd.)

Selected Charts

Classification and Application of Blood Products

Comparison between Recombinant Blood Products and Conventional Blood Products

Classification and Comparison of Domestic and Foreign Recombinant Blood Products

Blood Product Industry Chain

China's Blood Product Market Size, 2003-2015E

Prices of Some Blood Products in China, 2013

Lot Release Volume of Blood Products in China (by Product), 2007-2012

China's Blood Product Structure (by Lot Release Volume), 2009-2012

China's Plasma Volume, 2002-2012

Plasma Station Distribution in China by Region, Jun 2013

Health Insurance Coverage of Mainstream Blood Products in China

Comparison between China and Developed Countries by Per Capita Consumption of Blood Products

Plasma Station Distribution, Plasma Volume and Blood Product Revenue of Major Blood Product Enterprises in China, 2012

Comparison among Domestic Blood Product Producers by Product Line

Global Blood Product Structure

Blood Products Available in Foreign Markets

Ongoing Clinical Trials of New Indications in Foreign Countries

Global Producers of Blood Products

Main Policies for Blood Products in China

Industrial Sales Output Value and Total Profit of China's Biological and Biochemical Manufacturing Industry, 2008-2012

Human Serum Albumin Prices in China, 2003-2012

Domestic and Imported Human Serum Albumin in China (by Lot Release Volume), 2007-2012

Market Share of Major Producers of Human Serum Albumin in China (by Lot Release Volume), 2008-2012

Comparison between China and USA by Consumption of Human Immunoglobulin for Intravenous Injection, 2010

Lot Release Volume and Growth Rate of Human Immunoglobulin (pH4) for Intravenous Injection in China, 2007-2012

Comparison between China and Other Countries by Price of Human Immunoglobulin (pH4) for Intravenous Injection

Market Share of Major Producers of Human Immunoglobulin (pH4) for Intravenous Injection in China (by Lot Release Volume), 2007-2012

Lot Release Volume and Growth Rate of Coagulation Factor VIII in China, 2008-2012

Market Share of Human Coagulation Factor VIII Producers in China (by Lot Release Volume), 2008-2012

Comparison between Human-derived Coagulation Factor VIII and Recombinant Coagulation Factor VIII

Lot Release Volume and Growth Rate of Hepatitis B Immunoglobulin in China, 2008-2012

Market Share of Major Hepatitis B Immunoglobulin Enterprises in China (by Lot Release Volume), 2008-2012

Prices of Human Immunoglobulin in China by Dosage Form, 2013

Lot Release Volume and Growth Rate of Human Immunoglobulin in China, 2008-2012

Market Share of Major Human Immunoglobulin Enterprises in China (by Lot Release Volume), 2008-2012

Lot Release Volume and Growth Rate of Human Prothrombin Complex in China, 2009-2012

Market Share of Human Prothrombin Complex Enterprises in China (by Lot Release Volume), 2008-2012

Lot Release Volume and Growth Rate of Tetanus Immunoglobulin in China, 2008-2012

Market Share of Major Tetanus Immunoglobulin Enterprises in China (by Lot Release Volume), 2008-2012

Lot Release Volume and Growth Rate of Rabies Immunoglobulin in China, 2008-2012

Market Share of Major Rabies Immunoglobulin Enterprises in China (by Lot Release Volume), 2008-2012

Shareholding Structure of China Biologic Products, 2012

Revenue and Operating Income of China Biologic Products, 2007-2012

Revenue of China Biologic Products (by Product), 2011-2012

Revenue Structure of China Biologic Products (by Product), 2010-2012

Revenue Contribution and % of Total Revenue of China Biologic Products' Top Five Customers, 2008-2012

R&D Investment and % of Revenue of China Biologic Products, 2010-2012

New Products under Research by China Biologic Products, 2012

Lot Release Volume of Blood Products of Shandong Taibang, 2008-2012

Lot Release Volume of Blood Products of Guiyang Qianfeng, 2007-2011

Lot Release Volume of Blood Products of Xi'an Hui Tian, 2008-2012

Revenue and Operating Income of China Biologic Products, 2012-2015

Revenue and Total Profit of Hualan Biological Engineering, 2007-2012

Revenue of Hualan Biological Engineering (by Sector), 2007-2012

Revenue of Hualan Biological Engineering (by Product), 2007-2012

Revenue of Hualan Biological Engineering (by Region), 2007-2012

Gross Margin of Hualan Biological Engineering (by Sector), 2007-2012

Gross Margin of Hualan Biological Engineering (by Product), 2007-2012

Revenue Contribution and % of Total Revenue of Hualan Biological Engineering's Top Five Customers, 2007-2012

Procurement of Hualan Biological Engineering from Top Five Suppliers, 2007-2012

R&D Investment and % of Total Revenue of Hualan Biological Engineering, 2007-2012

Blood Product Types and Specifications of Hualan Biological Engineering

Plasma Collection Distribution of Hualan Biological Engineering, May 2013

Lot Release Volume of Blood Products of Hualan Biological Engineering, 2008-2012

Blood Product Revenue and Gross Margin of Hualan Biological Engineering, 2007-2012

Blood Product Revenue and Gross Margin of Hualan Biological Engineering (by Product), 2007-2012

Revenue and Operating Income of Hualan Biological Engineering, 2012-2015E

Plasma Station Distribution of Shanghai RAAS, 2012

Revenue and Operating Income of Shanghai RAAS, 2007-2012

Lot Release Volume of Blood Products of Shanghai RAAS, 2008-2012

Revenue of Shanghai RAAS (by Product), 2007-2012

Revenue of Shanghai RAAS (by Region), 2007-2012

Gross Margin of Shanghai RAAS (by Product), 2007-2012

Revenue Contribution of Shanghai RAAS' Top Five Customers, 2007-2012

Name List and Revenue Contribution of Shanghai RAAS' Top Five Customers, 2012

Procurement of Shanghai RAAS from Top Five Suppliers, 2007-2012

R&D Costs and % of Revenue of Shanghai RAAS, 2007-2012

Revenue and Operating Income of Shanghai RAAS, 2012-2015E

Major Subsidiaries and Their Revenue and Net Income of Beijing Tiantan Biological Products, 2012

Revenue and Total Profit of Beijing Tiantan Biological Products, 2007-2012

Revenue of Beijing Tiantan Biological Products (by Sector), 2007-2012

Revenue of Beijing Tiantan Biological Products (by Region), 2007-2012

Gross Margin of Beijing Tiantan Biological Products (by Sector), 2007-2012

Procurement of Beijing Tiantan Biological Products from Top Five Suppliers, 2007-2012

Revenue Contribution and % of Total Revenue of Beijing Tiantan Biological Products' Top Five Customers, 2007-2012

Name List and Revenue Contribution of Beijing Tiantan Biological Products' Top Five Customers, 2012

R&D Costs and % of Revenue of Beijing Tiantan Biological Products, 2009-2012

Plasma Station Distribution of Beijing Tiantan Biological Products, 2012

Blood Product Revenue and Gross Margin of Beijing Tiantan Biological Products, 2007-2012

Lot Release Volume of Blood Products of Chengdu Ronsen and Tiantan Chongqing, 2008-2012

Revenue and Operating Income of Beijing Tiantan Biological Products, 2012-2015

Revenue and Operating Income of Zhenxing Biopharmaceutical & Chemical, 2009-2012

Operating Revenue of Zhenxing Biopharmaceutical & Chemical (by Product), 2009-2012

Operating Revenue of Zhenxing Biopharmaceutical & Chemical (by Region), 2009-2012

Gross Margin of Zhenxing Biopharmaceutical & Chemical (by Product), 2009-2012

Revenue Contribution of Zhenxing Biopharmaceutical & Chemical's Top Five Customers, 2009-2012

Name List and Revenue Contribution of Zhenxing Biopharmaceutical & Chemical's Top Five Customers, 2012

Procurement of Zhenxing Biopharmaceutical & Chemical from Top Five Suppliers, 2012

R&D Costs and % of Revenue of Zhenxing Biopharmaceutical & Chemical, 2009-2012

R&D Progress of Zhenxing Biopharmaceutical & Chemical, 2012

Plasma Volume of Shuanglin Bio-pharmacy, 2010-2012

Plasma Station Distribution of Shuanglin Bio-pharmacy, 2012

Blood Product Output, Sales Volume and Inventory of Zhenxing Biopharmaceutical & Chemical, 2011-2012

Lot Release Volume of Blood Products of Shuanglin Bio-pharmacy, 2008-2012

Blood Product Revenue and Gross Margin of Zhenxing Biopharmaceutical & Chemical, 2009-2012

Revenue and Operating Income of Zhenxing Biopharmaceutical & Chemical, 2012-2015E

Plasma Collection Volume of Jiangxi Boya Bio-pharmaceutical, 2008-2012

Revenue and Operating Income of Jiangxi Boya Bio-pharmaceutical, 2009-2012

Revenue of Jiangxi Boya Bio-pharmaceutical (by Product), 2009-2012

Lot Release Volume of Blood Products of Jiangxi Boya Bio-pharmaceutical, 2011-2012

Revenue of Jiangxi Boya Bio-pharmaceutical (by Region), 2009-2012

Gross Margin of Jiangxi Boya Bio-pharmaceutical (by Product), 2009-2012

Revenue Contribution and % of Total Revenue of Jiangxi Boya Bio-pharmaceutical's Top Five Customers, 2009-2012

Name List and Revenue Contribution of Jiangxi Boya Bio-pharmaceutical's Top Five Customers, 2012

Procurement of Jiangxi Boya Bio-pharmaceutical from Top Five Suppliers, 2009-2012

R&D Costs and % of Revenue of Jiangxi Boya Bio-pharmaceutical, 2009-2012

Revenue and Operating Income of Jiangxi Boya Bio-pharmaceutical, 2012-2015E

Plasma Station Distribution of Sichuan Yuanda Shuyang Pharmaceutical, 2012

Lot Release Volume of Blood Products of Sichuan Yuanda Shuyang Pharmaceutical, 2008-2012

Lot Release Volume of Blood Products of CNBG Shanghai Institute of Biological Products, 2008-2012

Plasma Station Distribution of CNBG Shanghai Institute of Biological Products, 2012

Plasma Station Distribution of Shanxi Kangbao Biological Product, 2012

Lot Release Volume of Blood Products of Shanxi Kangbao Biological Product, 2008-2012

Plasma Station Distribution of Green Cross China, 2012

Lot Release Volume of Blood Products of Green Cross China, 2008-2012

Revenue and Operating Income of Humanwell Healthcare, 2007-2012

Lot Release Volume of Blood Products of Wuhan Zhongyuan Ruide Biological Products, 2008-2012

Industrial Distribution of Walvax Biotechnology

Revenue and Operating Income of Walvax Biotechnology, 2007-2012

To order this report:Blood_Supply,_Tissue_Banking_and_Transplantation Industry: China Blood Product Industry Report, 2012-2015

Contact Clare: [email protected]

US:(339) 368 6001

Intl:+1 339 368 6001

SOURCE Reportlinker